Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 51

Sort by

Sort Order Select

Journal Articles

A Phase II Trial of Prophylactic Anakinra to Prevent Neurotoxicity in Patients Receiving Anti-CD19 CAR T-Cell Therapy for Relapsed or Refractory Lymphoma: Final Results from Cohort 2

Blood (2023) 142 (Supplement 1): 357.

https://doi.org/10.1182/blood-2023-174728

Published: 2023

Journal Articles

Role of Cell Therapy Product Characteristics in Patient Response to TAK-940 (CD19(T2)28z1xx Chimeric Antigen Receptor (CAR) T): Biomarker Analyses from a Phase I Study in Adult Patients with Relapsed or Refractory B-Cell Malignancies

Varsha Sundaresan, Brigitte Senechal, Xiuyan Wang, Shubhra Kashyap, Erica Tong, Adarsh Joshi, Ajeeta Dash, Leopold Sellner, Sharon Chen, Devin McAvoy, Kinga K Hosszu, Devanjan S Sikder, Isabelle Riviere, Michel Sadelain, Jae H. Park, Reshma Singh

Blood (2023) 142 (Supplement 1): 349.

https://doi.org/10.1182/blood-2023-177712

Published: 2023

Journal Articles

A Phase I Study of CD19-Targeted 19(T2)28z1xx CAR T Cells in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Jae H. Park, Maria Lia Palomba, Sean M. Devlin, Yannis K. Valtis, Devanjan S Sikder, Brigitte Senechal, Xiuyan Wang, Elizabeth Cathcart, Kelly Liotta, Alina Yu, Kelsey Stocker, Honglei Zhang, Heiko Schoder, Doris Leithner, Jia Li, Leopold Sellner, Jorge Mansilla-Soto, Isabelle Riviere, Michel Sadelain

Blood (2023) 142 (Supplement 1): 892.

https://doi.org/10.1182/blood-2023-187623

Published: 2023

Journal Articles

Long Term Follow-up after Treatment with Allogeneic Off-the-Shelf CAR T Cell Therapy for Relapsed or Refractory B-Cell Malignancies

Sanam Shahid, Georgia C Flynn, Audrey Mauguen, Jennifer Bieler, Susan E Prockop, Andromachi Scaradavou, Jaap Jan Boelens, Craig S Sauter, Miguel-Angel Perales, Sergio A. Giralt, Xiuyan Wang, Isabelle Riviere, Michel Sadelain, Renier Brentjens, Nancy A Kernan, Richard J O'Reilly, Kevin J Curran

Blood (2023) 142 (Supplement 1): 3476.

https://doi.org/10.1182/blood-2023-180753

Published: 2023

Journal Articles

The Development of Allogeneic Tips-Derived TCR - CAR + CD8αβ T Cells

Sjoukje J.C. van der Stegen, Roseanna M. Petrovic, Pieter L. Lindenbergh, Mame P. Diop, Vera Alexeeva, Hongyao Xie, Raedun Clarke, Bahram Valamehr, Isabelle Rivière, Michel Sadelain

Blood (2022) 140 (Supplement 1): 10290–10291.

https://doi.org/10.1182/blood-2022-169375

Published: 2022

Journal Articles

A Phase I Study of CD19-Targeted 19(T2)28z1xx CAR T Cells in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Jae H Park, M. Lia Palomba, Isabelle Rivière, Devanjan S. Sikder, Brigitte Senechal, Xiuyan Wang, Vladimir P. Bermudez, Elizabeth R. Cathcart, Kelly Liotta, Jannakie Joseph, Jia Li, Yunqi Zhao, Rachael Liu, Sharon Chen, Leopold Sellner, Michel Sadelain

Blood (2022) 140 (Supplement 1): 403–404.

https://doi.org/10.1182/blood-2022-168206

Published: 2022

Journal Articles

Target Densities in Malignant and Normal Cells Determine CAR T Cell Efficacy and Off-Target Hematotoxicity

Sascha Haubner, Jorge Mansilla-Soto, Sarah Nataraj, Friederike Kogel, Qing Chang, Elisa De Stanchina, Kathryn Fraser, Jae H Park, Xiuyan Wang, Isabelle Rivière, Michel Sadelain

Blood (2022) 140 (Supplement 1): 869–870.

https://doi.org/10.1182/blood-2022-162968

Published: 2022

Journal Articles

The Intestinal Microbiota Correlates with Response and Toxicity after CAR T Cell Therapy in Patients with B-Cell Malignancies

Blood (2021) 138 (Supplement 1): 253.

https://doi.org/10.1182/blood-2021-153945

Published: 2021

Journal Articles

"IF-Better" Gating: Combinatorial Targeting and Synergistic Signaling for Enhanced CAR T Cell Efficacy

Sascha Haubner, Jorge Mansilla-Soto, Sarah Nataraj, Xingyue He, Jae H Park, Xiuyan Wang, Isabelle Rivière, Michel Sadelain

Blood (2021) 138 (Supplement 1): 2774.

https://doi.org/10.1182/blood-2021-149263

Published: 2021

Journal Articles

Clinical Manufacture of FT819: Use of a Clonal Multiplexed-Engineered Master Induced Pluripotent Stem Cell Line to Mass Produce Off-the-Shelf CAR T-Cell Therapy

Blood (2021) 138 (Supplement 1): 1766.

https://doi.org/10.1182/blood-2021-152985

Published: 2021

Journal Articles

Phase I First-in-Class Trial of MCARH109, a G Protein Coupled Receptor Class C Group 5 Member D (GPRC5D) Targeted CAR T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma

Blood (2021) 138 (Supplement 1): 827.

https://doi.org/10.1182/blood-2021-153204

Published: 2021

Journal Articles

Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy

Kitsada Wudhikarn, Jessica R. Flynn, Isabelle Rivière, Mithat Gönen, Xiuyan Wang, Brigitte Senechal, Kevin J. Curran, Mikhail Roshal, Peter G. Maslak, Mark B. Geyer, Elizabeth F. Halton, Claudia Diamonte, Marco L. Davila, Michel Sadelain, Renier J. Brentjens, Jae H. Park

Blood (2021) 138 (7): 531–543.

https://doi.org/10.1182/blood.2020009515

Published: 2021

Includes: Supplemental data

Journal Articles

A Phase I Study of CD19-Targeted 19(T2)28z1xx CAR T Cells in Adult Patients with Relapsed or Refractory B-Cell Malignancies

Jae H. Park, MD, Isabelle Riviere, PhD, Devanjan S. Sikder, Vladimir P. Bermudez, Brigitte Senechal, Xiuyan Wang, PhD, Thomas H. Auchincloss, Claudia Diamonte, RN, Elizabeth Halton, NP-BC AOCNP, M. Lia Palomba, MD, Renier J. Brentjens, MD PhD, Michel Sadelain, MD PhD

Blood (2020) 136 (Supplement 1): 43–44.

https://doi.org/10.1182/blood-2020-143088

Published: 2020

Journal Articles

NOTCH and CAR Signaling Control T Cell Lineage Commitment from Pluripotent Stem Cells

Sjoukje van der Stegen, PhD, Pieter Lindenbergh, Roseanna Petrovic, PhD, Benjamin Whitlock, PhD, Raedun Clarke, PhD, Bahram Valamehr, PhD, Isabelle Riviere, PhD, Michel Sadelain, MD PhD

Blood (2020) 136 (Supplement 1): 30.

https://doi.org/10.1182/blood-2020-142894

Published: 2020

Journal Articles

Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL

Blood (2019) 134 (26): 2361–2368.

https://doi.org/10.1182/blood.2019001641

Published: 2019

Includes: Supplemental data

Journal Articles

FT819: Translation of Off-the-Shelf TCR-Less Trac-1XX CAR-T Cells in Support of First-of-Kind Phase I Clinical Trial

Blood (2019) 134 (Supplement_1): 4434.

https://doi.org/10.1182/blood-2019-130584

Published: 2019

Journal Articles

Clinical Factors Associated with Improved Survival Following Allogeneic HSCT after CD19 CAR Therapy in Adult Patients with Relapsed B-ALL

Jae H. Park, MD, Jessica Flynn, BS, Mithat Gonen, Yvette Bernal, MS, Claudia Diamonte, RN, Elizabeth Halton, NP-BC AOCNP, Xiuyan Wang, PhD, Isabelle Riviere, PhD, Michel Sadelain, MD PhD, Renier J. Brentjens, MD PhD

Blood (2019) 134 (Supplement_1): 1348.

https://doi.org/10.1182/blood-2019-129343

Published: 2019

Journal Articles

CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma

Blood (2019) 134 (7): 626–635.

https://doi.org/10.1182/blood.2018883421

Published: 2019

Includes: Supplemental data

Journal Articles

Pluripotent Cell-Derived Off-the-Shelf TCR-Less CAR-Targeted Cytotoxic T Cell Therapeutic for the Allogeneic Treatment of B Cell Malignancies

Blood (2018) 132 (Supplement 1): 4546.

https://doi.org/10.1182/blood-2018-99-116843

Published: 2018

Journal Articles

Clinical Responses and Pharmacokinetics of MCARH171, a Human-Derived Bcma Targeted CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma: Final Results of a Phase I Clinical Trial

Blood (2018) 132 (Supplement 1): 959.

https://doi.org/10.1182/blood-2018-99-119717

Published: 2018

NARROW

A Phase II Trial of Prophylactic Anakinra to Prevent Neurotoxicity in Patients Receiving Anti-CD19 CAR T-Cell Therapy for Relapsed or Refractory Lymphoma: Final Results from Cohort 2

Role of Cell Therapy Product Characteristics in Patient Response to TAK-940 (CD19(T2)28z1xx Chimeric Antigen Receptor (CAR) T): Biomarker Analyses from a Phase I Study in Adult Patients with Relapsed or Refractory B-Cell Malignancies

A Phase I Study of CD19-Targeted 19(T2)28z1xx CAR T Cells in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Long Term Follow-up after Treatment with Allogeneic Off-the-Shelf CAR T Cell Therapy for Relapsed or Refractory B-Cell Malignancies

The Development of Allogeneic Tips-Derived TCR - CAR + CD8αβ T Cells

A Phase I Study of CD19-Targeted 19(T2)28z1xx CAR T Cells in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Target Densities in Malignant and Normal Cells Determine CAR T Cell Efficacy and Off-Target Hematotoxicity

The Intestinal Microbiota Correlates with Response and Toxicity after CAR T Cell Therapy in Patients with B-Cell Malignancies

"IF-Better" Gating: Combinatorial Targeting and Synergistic Signaling for Enhanced CAR T Cell Efficacy

Clinical Manufacture of FT819: Use of a Clonal Multiplexed-Engineered Master Induced Pluripotent Stem Cell Line to Mass Produce Off-the-Shelf CAR T-Cell Therapy

Phase I First-in-Class Trial of MCARH109, a G Protein Coupled Receptor Class C Group 5 Member D (GPRC5D) Targeted CAR T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma

Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy

A Phase I Study of CD19-Targeted 19(T2)28z1xx CAR T Cells in Adult Patients with Relapsed or Refractory B-Cell Malignancies

NOTCH and CAR Signaling Control T Cell Lineage Commitment from Pluripotent Stem Cells

Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL

FT819: Translation of Off-the-Shelf TCR-Less Trac-1XX CAR-T Cells in Support of First-of-Kind Phase I Clinical Trial

Clinical Factors Associated with Improved Survival Following Allogeneic HSCT after CD19 CAR Therapy in Adult Patients with Relapsed B-ALL

CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma

Pluripotent Cell-Derived Off-the-Shelf TCR-Less CAR-Targeted Cytotoxic T Cell Therapeutic for the Allogeneic Treatment of B Cell Malignancies

Clinical Responses and Pharmacokinetics of MCARH171, a Human-Derived Bcma Targeted CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma: Final Results of a Phase I Clinical Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only